• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Nutraceuticals
    • Markets
    • Health
    • Jobs
    • Events
    • Buyers' Guide
    • Showcases
    • More
  • Magazine
  • News
  • Exclusives
  • Nutraceuticals
  • Markets
  • Health
  • Jobs
  • Events
  • Buyers' Guide
  • Showcases
  • Current & Past Issues
    Features
    Columns
    Editorials
    Digital Edition
    Subscribe Now
    Advertise Now
    eNewsletter
    Editorial Guidelines
    Top Features
    Health Products Association - China Executive Director Reflects on Market Dynamics, Challenges

    Blood Sugar Management: Personalized Testing Drives Home The Need for Early Intervention

    New and Evolving Formulation Options Must Be Mindful of Blood Sugar Maintenance

    Tapping Functional Beverages to Meet Modern Wellness Needs

    Adaptogens: Where Ancient Remedies Meet Modern Wellness Products
    Breaking News
    Certifications, Approvals and Patents
    Exclusives
    Industry & Market News
    People
    Products
    Regulatory
    Research
    Supplier News
    Supplier Insights
    Live From Shows
    Top News
    Florida Food Products Acquires Javo

    Roquette Launches Nutralys Rice Protein

    New IADSA Chair Lauds Explorations of Supplementation in Healthcare Policy

    CTRL Launches Meal On-The-Go Bars

    GNC and RealEats Meal Delivery Partnership Expands Nationally
    Exclusives
    Blogs & Guest Articles
    Health E-Insights
    Area Code 420
    eBook
    Antioxidants
    Dairy-Based Ingredients
    Enzymes
    Fatty Acids
    Fiber & Carbohydrates
    Green Foods
    Herbs & Botanicals
    Marine Nutraceuticals
    Minerals
    Omega 3s
    Probiotics & Prebiotics
    Proteins, Peptides, Amino Acids
    Sweeteners
    Vitamins

    Roquette Launches Nutralys Rice Protein

    Upcycled Coffeeberry® Cascara Offers Versatility in Functional Beverage Development

    Study Reveals Low Intake of Tocotrienols in Polish Population

    Combination of Collagen and Boswellia Serrata Shown to Reduce Joint Discomfort

    Nutralliance Adds Eggshell-Derived Ingredients for Beauty and Joint Health to Portfolio
    Consumer Trends
    Contract Manufacturing
    Cosmeceuticals / Nutricosmetics
    Delivery & Dosage Technologies
    Dietary Supplements
    Flavors & Colors
    Functional Foods & Beverages
    Healthcare Trends
    Medical Nutrition
    Mergers & Acquisitions
    Natural/Organic
    Nutrition Bars
    Packaging
    Pet Nutraceuticals
    Quality & Safety
    Regulations
    Research
    Testing
    World Markets

    Florida Food Products Acquires Javo

    Roquette Launches Nutralys Rice Protein

    New IADSA Chair Lauds Explorations of Supplementation in Healthcare Policy

    CTRL Launches Meal On-The-Go Bars

    Upcycled Coffeeberry® Cascara Offers Versatility in Functional Beverage Development
    Bone & Joint Health
    Cancer Risk
    Cardiovascular Health
    Cognitive Function
    Diabetes & Blood Sugar Management
    Digestive Health
    Energy
    Eye Health
    Healthy Aging
    Immune Function
    Infant & Children's Health
    Inflammation
    Men's Health
    Mood Health & Sleep
    Oral Health
    Sexual & Reproductive Health
    Skin Health
    Sports Nutrition
    Weight Management/Weight Loss
    Women's Health

    Upcycled Coffeeberry® Cascara Offers Versatility in Functional Beverage Development

    Botanical Gum for Kids Aims to Curb Sugar Cravings

    Combination of Collagen and Boswellia Serrata Shown to Reduce Joint Discomfort

    Childhood Fitness and Obesity Impact Cognition Later in Life, Study Finds

    Nutralliance Adds Eggshell-Derived Ingredients for Beauty and Joint Health to Portfolio
    Industry Events
    Live From Show Events
    Webinars
    All Companies
    Categories
    Trade Associations
    Company Capabilities
    International Buyers Guide Companies
    Nutrition21, LLC

    Atlantia Clinical Trials

    KLK OLEO

    Botanic Healthcare LLC

    PhytoGaia Inc
    Companies
    Product Releases
    News Releases
    Literature / Brochures
    White Papers
    Jobs
    VIdeos
    Services
    Add New Company
    International Buyers Guide Companies
    Nutrition21, LLC

    Atlantia Clinical Trials

    KLK OLEO

    Botanic Healthcare LLC

    PhytoGaia Inc
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • All Companies
      • Categories
      • Trade Associations
      • Company Capabilities
    • Nutraceuticals
      • Antioxidants
      • Dairy-Based Ingredients
      • Enzymes
      • Fatty Acids
      • Fiber & Carbohydrates
      • Green Foods
      • Herbs & Botanicals
      • Marine Nutraceuticals
      • Minerals
      • Omega 3s
      • Probiotics & Prebiotics
      • Proteins, Peptides, Amino Acids
      • Sweeteners
      • Vitamins
    • Markets
      • Consumer Trends
      • Contract Manufacturing
      • Cosmeceuticals / Nutricosmetics
      • Delivery & Dosage Technologies
      • Dietary Supplements
      • Flavors & Colors
      • Functional Foods & Beverages
      • Healthcare Trends
      • Medical Nutrition
      • Mergers & Acquisitions
      • Natural/Organic
      • Nutrition Bars
      • Packaging
      • Pet Nutraceuticals
      • Quality & Safety
      • Regulations
      • Research
      • Testing
      • World Markets
    • Health
      • Bone & Joint Health
      • Cancer Risk
      • Cardiovascular Health
      • Cognitive Function
      • Diabetes & Blood Sugar Management
      • Digestive Health
      • Energy
      • Eye Health
      • Healthy Aging
      • Immune Function
      • Infant & Children's Health
      • Inflammation
      • Men's Health
      • Mood Health & Sleep
      • Oral Health
      • Sexual & Reproductive Health
      • Skin Health
      • Sports Nutrition
      • Weight Management/Weight Loss
      • Women's Health
    • Online Exclusives
    • Webinars
    • Slideshows
    • Blogs & Guest Articles
    • Health E-Insights
    • Videos
    • Podcasts
    • Infographics
    • eBook
    • Whitepapers
    • Research
      • TrendSense
      • Monograph Center
      • White Papers
      • Research News
    • Jobs
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Supplier Showcases
      • Companies
      • Product Releases
      • News Releases
      • Literature / Brochures
      • White Papers
      • Jobs
      • VIdeos
      • Services
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    CBD Safety Assessment

    A flood of all types of consumer products in the marketplace warrants a review of available scientific evidence.

    CBD Safety Assessment
    By Marilyn Barrett, PhD, Pharmacognosy Consulting, Inc., Mary Ellen Cosenza, PhD, MEC Regulatory & Toxicology Consulting, Steven Dentali, PhD, Dentali Botanical Sciences, and Sandy Bigelow, PhD, Vanguard Global Associates LLC04.02.20
    Significant public interest and consumer acceptance of cannabidiol (CBD) over the last 2-3 years has created a burgeoning marketplace with estimated sales last year of $5 billion. It cannot be denied that products purporting to contain CBD are pervasive.

    CBD is a terpenoid-phenolic compound, one of a class of compounds called cannabinoids that are produced in the resinous hairs (glandular trichomes) of Cannabis sativa L. The group of 20-plus major cannabinoids includes other cannabinoids such as Δ9-tetrahydrocannabinol (THC), its degradation product cannabinol, cannabigerol, cannabichromene and tetrahydrocannabivarin. THC produces psychogenic effects that may be associated with habitual use via regular cannabis smoking or ingestion of edibles. CBD has been found not to exert psychogenic effects and not to promote habitual use, thus exhibiting a limited potential for abuse.

    Regulatory Matters
    Until recently, all products made from cannabis were categorized as schedule I drugs, as per the Controlled Substances Act of 1970 (21 USC §801). Schedule I drugs are substances with no currently accepted medical use and a high potential for abuse. The Farm Bill enacted in December 2018 removed hemp from Schedule I controlled substances, making it an ordinary agricultural commodity. Hemp is defined as cannabis with not more than 0.3% of THC. The passage of the 2018 Farm Bill led many people to believe that CBD could be sold legally as a dietary supplement.

    In 1985, the Food and Drug Administration (FDA) approved two synthetic (not found in nature) cannabinoid-based drugs—dronabidol and nabilone—for use in a variety of indications including treatment of pain; they appear to be used as alternatives to opiates in relieving pain and for treating nausea in patients undergoing chemotherapy. In June of 2018, the FDA approved a CBD product, Epidiolex, to be marketed as a drug for the treatment of seizures associated with Lennox-Gastaut or Dravet syndromes in patients two years of age and older.

    Because CBD was first publicly investigated as a drug, the FDA concluded that it may not be legally sold as an ingredient in dietary supplements; the Dietary Supplement Health and Education Act (DSHEA) excludes such materials by definition. To further complicate the issue, individual states have passed their own laws pertaining to cannabis and CBD that contradict the federal position.

    Product Profiles
    This regulatory conundrum has not presented a roadblock to the explosion of sales of CBD products in the U.S. Numerous CBD-containing products are sold as foods, cosmetics and dietary supplements in the U.S. marketplace. Foods containing CBD include flavored waters and beer. Topical CBD products include creams, sprays and salves. Dietary supplement CBD products include tinctures, extracts and oils, capsules, pills and gummies. CBD is also often taken via inhalation by smoking cannabis and in vaping products. All of these products are taken by consumers with the hope of treatment for ailments such as joint pain, back pain, muscle soreness, headache, occasional sleeplessness, anxiety or stress. CBD products for pet use are also emerging in the marketplace.

    Some products contain purified CBD as an isolated compound, while others contain tinctures or extracts with CBD in a matrix of other compounds—either naturally present in the cannabis plant like other cannabinoids, terpenes and flavonoids, or additional ingredients not present in cannabis but thought to enhance the activity of CBD.

    Safety Analysis
    This escalation of products into the marketplace begs consideration of the question of consumer safety. Safety reviews of products in the public domain proceed in a systematic manner. In this process, the scientific literature is reviewed for indications of potential hazards. Highest priority is placed on adverse effects reported in humans, in descending order from clinical trials and observational studies, to case reports and anecdotal evidence. Toxicologists examine the literature to determine if a causal relationship to reported adverse events can be determined. They ask if the event was observed after the product was taken, how consistent this effect is, if there is a dose-related effect, and if the adverse event is biologically plausible according to biochemical and pharmacological information.

    Most toxicological evidence used in risk assessments come from animal studies. Doses much higher than consumed by humans are used to reveal any possible toxic responses in animals. Once results from these studies are gathered, considerations are made for possible species differences in metabolism and pharmacology between the animals and humans. Considerations are given to sensitive subpopulations that might have responses (in terms of incidence, severity or both) that are different from the responses expected for the healthy population.

    An important preliminary step in any safety evaluation is consideration of the absorption of the ingredient into the body. Factors that affect absorption and the ingredient’s action in the body include its concentration and chemical form, the nutrition and health of the individual, and the process of metabolizing and excreting the ingredient via urine and feces.

    Reports show that CBD is a fat-soluble compound that exhibits limited bioavailability (absorption from the gut into the body) after oral use. Oral ingestion of 20 mg CBD by humans leads to maximal plasma CBD levels within two hours of initial exposure and a plasma half-life of about two hours. Ingesting CBD with fatty foods delays absorption from the gastrointestinal tract, yet once absorbed leads to higher plasma levels.

    The literature identifies three possible areas of concern: the risk of liver damage, the risk of reproductive impairment and the potential for CBD-drug interactions. The first concern is derived from clinical findings with Epidiolex, which showed that oral CBD ingestion caused mild dose-dependent elevations in serum liver enzyme levels. Elevation of serum liver enzymes was also observed in several animal studies following intake of various preparations of CBD. However, these concerns did not meet the criteria for drug-induced liver toxicity as there was no concurrent elevation of blood levels of bilirubin, a reddish-yellow pigment made during the normal breakdown of hemoglobin in red blood cells. In other words, there was no evidence of jaundice and there was no change in blood coagulation. The identified risks for elevation of liver enzymes following intake of CBD were identified with higher doses, already elevated levels of these enzymes (liver dysfunction) and taking another seizure medication.

    The second concern from toxicological studies conducted in animals indicate potential detrimental effects on reproductive health as a decrease in sperm production in monkeys and mice. In contrast, the FDA review of studies conducted with Epidiolex concluded no effects on male or female rodent reproductive indices. However, the FDA is concerned about the lack of safety information on CBD regarding reproductive health and has released a caution against the use of CBD in supplements by pregnant or breastfeeding women. More studies are warranted, but as pregnant and breastfeeding women are especially sensitive, caution is advised.

    Lastly, there is a concern that CBD might alter the concentration levels of certain medicines in the body. CBD is reported to be a broad-spectrum but weak inhibitor of some enzymes in the liver (cytochrome P-450 enzymes) which might alter the way that other drugs are metabolized. So far, studies conducted in humans have only explored the combination of the drug Epidiolex with other anti-seizure medications. The significance of these findings to potential interactions between more common medicinal agents with CBD has not been determined clinically. Clinical studies in humans will need to be conducted to address this drug interaction potential more fully.

    In summary, the evidence suggests that healthy adults are unlikely to exhibit liver problems following CBD ingestion. However, it may be unwise for those with symptoms of liver disease to take CBD. Symptoms of liver disease can vary, but they often include swelling of the abdomen and legs, bruising easily, dark color stools and urine, and yellowing of the skin and eyes. It is prudent for those women and men planning on a pregnancy, and women who are pregnant or breastfeeding, to limit their CBD ingestion or avoid it altogether. Finally, those currently on medications should seek advice from their healthcare professional before taking CBD products. Consumers should also be mindful of CBD dosage and resist combining multiple sources of CBD in one day. 
    Related Searches
    • Health
    • fda
    • Enzymes
    • Healthcare
    Related Knowledge Center
    • Quality & Safety
    • Regulations
    • Testing
    Trending
    • Three Grams Of Omega-3s May Be Optimal Dose For Reducing Blood Pressure
    • 3 grams of Omega-3s May be Optimal Dose for Reducing Blood Pressu
    • Olive/Pomegranate Extract May Improve Dyslipidemia
    Breaking News
    • Florida Food Products Acquires Javo
    • Roquette Launches Nutralys Rice Protein
    • New IADSA Chair Lauds Explorations of Supplementation in Healthcare Policy
    • CTRL Launches Meal On-The-Go Bars
    • GNC and RealEats Meal Delivery Partnership Expands Nationally
    View Breaking News >
    CURRENT ISSUE

    June 2022

    • Tapping Functional Beverages to Meet Modern Wellness Needs
    • Adaptogens: Where Ancient Remedies Meet Modern Wellness Products
    • New and Evolving Formulation Options Must Be Mindful of Blood Sugar Maintenance
    • Health Products Association - China Executive Director Reflects on Market Dynamics, Challenges
    • Blood Sugar Management: Personalized Testing Drives Home The Need for Early Intervention
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Florida Food Products Acquires Javo
    Roquette Launches Nutralys Rice Protein
    New IADSA Chair Lauds Explorations of Supplementation in Healthcare Policy
    Coatings World

    Latest Breaking News From Coatings World

    The Southern Society for Coatings Technology's 84th Annual Technical Conference A Success
    PPG to Showcase Specialty Automotive, Aerospace Adhesives, Sealants at Adhesives & Bonding Expo
    PPG’s New Paint for a New Start Initiative to Transform 25-plus Schools Worldwide
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MPO's Most Read Stories This Week—June 25
    Magnetic Insight Announces $17 Million in Series B Funding
    BreatheSuite Adds Brad Fluegel to its Board
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pierre Fabre and Lonza Enter Manufacturing Agreement
    MasterControl and Elemental Machines Form Biomanufacturing Partnership
    Qosina Strengthens Aseptic Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Benefit Exec Joins Madison Reed's Board
    Peroni & Ellis Brooklyn Launch Fragrance Collection Inspired by Italian Spritz Cocktails
    Rhode Is Trending for June, Trendalytics Says
    Happi

    Latest Breaking News From Happi

    A Suitor Emerges for Revlon, SK Capital’s New Dealmaker & P&G’s Indoor Air Quality Efforts
    Wonder Curl Wins GlossWire's GlossPitch Competition
    Anti-aging Skincare Brand Vitabrid C12 Launches Bestsellers on Amazon
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: INX’s VC Fund, Screen Industry and Ball Top This Week’s News
    British Coatings Federation Posts Online History
    Orion Announces Price Increases, Reduced Payment Terms
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    PCMC teams with IGT, Fujifilm makes big announcement and more
    Loftware recognized as 'AIDC Company of the Year'
    Schreiner MediPharm highlights sustainability of Needle-Trap technology
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Tranzonic Names VP of Supply Chain
    Ontex Climate Action Targets Approved by Science-Based Targets Initiative
    Suominen Test Center Assesses Biodegradability of Nonwovens
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT's Most-Read Stories This Week—June 25
    3Spine Inc. Receives IDE Approval for U.S. Pivotal Clinical Trial
    Volume-Based Procurement to Reduce Chinese Orthopedic Market Value
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: eMagin, Applied Materials, and Schott Top This Week’s Stories
    NREL Names Jennifer Logan to Leadership Team as CFO
    National Grid Renewables Orders 2 GW of First Solar Modules

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login